New version of ISO 10993-1: the core standard for the biological evaluation of medical devices

ISO 10993-1, the core standard for the biological evaluation of medical devices, has been under revision over the past few years. A Final Draft International St...

“Access to capital increases when there’s an exit”

It remains a tough environment for biotech companies seeking financing – but there is good reason to hope for improvement ahead. That’s the view of Okee William...

Join our measuringhero Jay on the innovation tour

Experience our latest innovation from the Control fair.

Acne medication may be the solution when hair starts falling out

A treatment originally developed for acne has shown remarkable Phase III results in a completely different area: male-pattern hair loss.

New moves around Nykode's management – withdrawal of resignations

Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.

Southern Swedish company Aqilion develops drug for eosinophilic esophagitis

When Aqilion began developing a drug for eosinophilic esophagitis, the molecule was classified as an orphan drug. But the prevalence of the disease now appears ...

Swedish life science is growing – but capital is not keeping up

The number of employees and companies in Swedish life science is increasing and the sector is more equal than many other sectors. But investments in unlisted co...

Optimera flödeshanteringen med Brooks Expert Support Tool (BEST)

Brooks Instrument erbjuder ett kraftfullt verktyg för dig som arbetar med digitala massflödesmätare och massflödesregulatorer. Med den Windows-baserade mjukvara...

FDA’s new CSA guidance: transforming software validation for production and quality systems

FDA’s final guidance on Computer Software Assurance (CSA) for Production and Quality System Software marks a significant modernization of software validation practices.

A cluster contribution to European life science innovation and competitiveness?

The FDA’s new transparency policy (Part 2)

In the second part of our article series on the FDA’s new “radical transparency” initiative, we explore regulatory strategies to navigate the potential impact o...

New findings on the diseases that crushed Napoleon’s army

As if cold, starvation, and typhus weren’t enough. New research reveals that Napoleon’s defeated army also suffered from paratyphoid fever and relapsing fever d...

Allogene discontinues investigational antibody following patient death

U.S. biotechnology company Allogene Therapeutics is fully discontinuing the use of its experimental antibody ALLO-647 following the death of a patient in its pi...

Sustainability at Festo

On the Way to the Net Zero Era - New Sustainability Report published

CT technology for when the inside matters

ZEISS METROTOM 1 now at #HandsOnMetrology.

Partial court victory for entrepreneur who lost his company

Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...

Novo Nordisk appoints Mike Doustdar as new CEO

The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts –...

Genmab to Acquire Dutch biotech for USD 8 Billion

Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.

Strategic Clarity: The New Currency in Life Science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...

Karolinska Development tar in kapital – och byter namn

Life science-investmentbolaget Karolinska Development föreslår en företrädesemission om cirka 203 miljoner kronor före transaktionskostnader.

Svenskt biotechbolag tar in 153 miljoner till cancerstudie

One-carbon Therapeutics, ett svenskt biotechbolag med inriktning på svårbehandlad cancer, har tagit in 153 miljoner kronor i en övertecknad investeringsrunda.

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Lundbeck kliver in i budstrid om narkolepsibolag

En budstrid har brutit ut om det irländska biotechbolaget Avadel Pharmaceuticals och dess potentiella storsäljare inom narkolepsi och hypersomni.

Agreement in the EU on eight years of data exclusivity for new medicines

New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...